While the clinical use of NK cell-based therapies for the treatment of infection and/or sepsis are still in development, our findings suggest TNF signaling is a highly valuable pathway and specific targeting of TNFR1 or TNFR2 could be exploited in the future of NK cell-based immunotherapies. This evidence concerns the gene TNFRSF1B and Sepsis.